Abstract
The spaceflight environment is at best, very different from Earth, and at worst (without the protection offered by the systems of a space suit or a spacecraft) deadly. Candidates for NASA’s astronaut program must meet many requirements to be selected, but even the healthiest people in the best circumstances use medications from time to time. During their spaceflight missions, astronauts are exposed to perhaps the most extreme of all extreme environments, and there are features of the spaceflight environment that drive uses of particular medications. This chapter will provide an overview of these mission-related medication needs and will discuss the special considerations that must be given to stocking the medication supplies for use on spaceflight missions.
This is a preview of subscription content, log in via an institution to check access.
References and Further Reading
Ahlstrand C, Tiselius HG (1987) Urine composition and stone formation during treatment with acetazolamide. Scand J Urol Nephrol 21(3):225–228
Alhnan MA, Okwuosa TC, Sadia M, Wan KW, Ahmed W, Arafat B (2016) Emergence of 3D printed dosage forms: opportunities and challenges. Pharm Res 33(8):1817–1832. https://doi.org/10.1007/s11095-016-1933-1
Arendt J, Van Someren EJ, Appleton R, Skene DJ, Akerstedt T (2008) Clinical update: melatonin and sleep disorders. Clin Med 8(4):381–383
Armaghani SJ, Crucian GP, Heilman KM (2014) The influence of emotional faces on the spatial allocation of attention. Brain Cogn 91:108–112. https://doi.org/10.1016/j.bandc.2014.09.006
Barger LK, Flynn-Evans EE, Kubey A, Walsh L, Ronda JM, Wang W, Wright KP Jr, Czeisler CA (2014) Prevalence of sleep deficiency and use of hypnotic drugs in astronauts before, during, and after spaceflight: an observational study. Lancet Neurol 13(9):904–912. https://doi.org/10.1016/S1474-4422(14)70122-X
Carpentier W, Charles JB, Shelhamer M, Hackler AS, Johnson TL, Domingo CMM, GBI S, Wotring VE (2018) Biomedical findings from NASA’s project mercury: a case series. npj Microgravity 4(6). https://doi.org/10.1038/s41526-018-0040-5
Chancellor JC, Scott GB, Sutton JP (2014) Space radiation: the number one risk to astronaut health beyond low earth orbit. Life (Basel) 4(3):491–510. https://doi.org/10.3390/life4030491
Cintrón NM, Putcha L, Chen Y-M, Vanderploeg JM (eds) (1987) In-flight salivary pharmacokinetics of scopolamine and dextroamphetamine. In: Results of the life sciences DSOs conducted aboard the space shuttle 1981–1986. Space Biomedical Research Institute, Johnson Space Center, Houston
Crucian B, Johnston S, Mehta S, Stowe R, Uchakin P, Quiriarte H, Pierson D, Laudenslager ML, Sams C (2016) A case of persistent skin rash and rhinitis with immune system dysregulation onboard the international Space Station. J Allergy Clin Immunol Pract 4(4):759–762., e758. https://doi.org/10.1016/j.jaip.2015.12.021
Cucinotta FA, Kim MHY, Chapell LJ (2010) Space radiation cancer risk projections and uncertainties – 2010. vol TP-2011-216155 NASA TP-2011-216155. NASA Center for AeroSpace Information, Hanover
Davis JR, Vanderploeg JM, Santy PA, Jennings RT, Stewart DF (1988) Space motion sickness during 24 flights of the space shuttle. Aviat Space Environ Med 59(12):1185–1189
Dijk DJ, Neri DF, Wyatt JK, Ronda JM, Riel E, Ritz-De Cecco A, Hughes RJ, Elliott AR, Prisk GK, West JB, Czeisler CA (2001) Sleep, performance, circadian rhythms, and light-dark cycles during two space shuttle flights. Am J Phys Regul Integr Comp Phys 281(5):R1647–R1664
Du B, Daniels V, Vaksman Z, Boyd J, Crady C, Putcha L (2011) Evaluation of physical and chemical changes in pharmaceuticals flown on space missions. AAPS J 13(2):299–308
Estrada A, Kelley AM, Webb CM, Athy JR, Crowley JS (2012) Modafinil as a replacement for dextroamphetamine for sustaining alertness in military helicopter pilots. Aviat Space Environ Med 83(6):556–564
FDA (2017) CDER researchers explore the promise and potential of 3D printed pharmaceuticals. Food and Drug Adminstration https://www.fda.gov/Drugs/NewsEvents/ucm588136.htm. Accessed 4 Apr 2018
Flynn-Evans EE, Barger LK, Kubey AA, Sullivan JP, Czeisler CA (2016) Circadian misalignment affects sleep and medication use before and during spaceflight. npj Microgravity 2. https://doi.org/10.1038/npjmgrav.2015.19
Fond G, Micoulaud-Franchi JA, Brunel L, Macgregor A, Miot S, Lopez R, Richieri R, Abbar M, Lancon C, Repantis D (2015) Innovative mechanisms of action for pharmaceutical cognitive enhancement: a systematic review. Psychiatry Res 229(1–2):12–20. https://doi.org/10.1016/j.psychres.2015.07.006
Fucci RL, Gardner J, Hanifin JP, Jasser S, Byrne B, Gerner E, Rollag M, Brainard GC (2005) Toward optimizing lighting as a countermeasure to sleep and circadian disruption in space flight. Acta Astronaut 56(9–12):1017–1024
Goel N, Dinges DF (2012) Predicting risk in space: genetic markers for differential vulnerability to sleep restriction. Acta Astronaut 77:207–213. https://doi.org/10.1016/j.actaastro.2012.04.002
Hershkovitz D, Asna N, Shupak A, Kaminski G, Bar R, Tal D (2009) Ondansetron for the prevention of seasickness in susceptible sailors: an evaluation at sea. Aviat Space Environ Med 80(7):643–646
Homick JL (1979) Space motion sickness. Acta Astronaut 6(10):1259–1272
Hu S, Kim MH, McClellan GE, Cucinotta FA (2009) Modeling the acute health effects of astronauts from exposure to large solar particle events. Health Phys 96(4):465–476. https://doi.org/10.1097/01.HP.0000339020.92837.61
Jennings RT (1998) Managing space motion sickness. J Vestib Res 8(1):67–70. https://doi.org/10.1016/S0957-4271(97)00042-6
Johnston S (2010) Operational ground testing protocol to optimize astronaut sleep medication efficacy and individual effects. https://taskbook.nasaprs.com/publication/index.cfm?action=public_query_taskbook_content&TASKID=8225. Accessed 4/3/2018
Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA (2002) Recent patterns of medication use in the ambulatory adult population of the United States: the slone survey. JAMA 287(3):337–344
Keasling JD (2010) Manufacturing molecules through metabolic engineering. Science 330(6009):1355–1358. https://doi.org/10.1126/science.1193990
Kovachevich I, Kondratenko S, Starodubtsev AK, Repenkova LG (2009) Pharmacokinetics of acetaminophen administered in tablets and capsules under long-term space flight conditions. Pharm Chem J 43(3):130–133
Law J, Van Baalen M, Foy M, Mason SS, Mendez C, Wear ML, Meyers VE, Alexander D (2014) Relationship between carbon dioxide levels and reported headaches on the international space station. J Occup Environ Med 56(5):477–483. https://doi.org/10.1097/jom.0000000000000158
Lawley JS, Petersen LG, Howden EJ, Sarma S, Cornwell WK, Zhang R, Whitworth LA, Williams MA, Levine BD (2017) Effect of gravity and microgravity on intracranial pressure. J Physiol 595(6):2115. https://doi.org/10.1113/jp273557
LeBlanc A, Matsumoto T, Jones J, Shapiro J, Lang T, Shackelford L, Smith SM, Evans H, Spector E, Ploutz-Snyder R, Sibonga J, Keyak J, Nakamura T, Kohri K, Ohshima H (2013) Bisphosphonates as a supplement to exercise to protect bone during long-duration spaceflight. Osteoporos Int 24(7):2105–2114. https://doi.org/10.1007/s00198-012-2243-z
Lee AG, Mader TH, Gibson CR, Brunstetter TJ, Tarver WJ (2018) Space flight-associated neuro-ocular syndrome (SANS). Eye (Lond). https://doi.org/10.1038/s41433-018-0070-y
Lockley SW, Brainard GC, Czeisler CA (2003) High sensitivity of the human circadian melatonin rhythm to resetting by short wavelength light. J Clin Endocrinol Metab 88(9):4502–4505. https://doi.org/10.1210/jc.2003-030570
Mader TH, Gibson CR, Pass AF, Kramer LA, Lee AG, Fogarty J, Tarver WJ, Dervay JP, Hamilton DR, Sargsyan A, Phillips JL, Tran D, Lipsky W, Choi J, Stern C, Kuyumjian R, Polk JD (2011) Optic disc edema, globe flattening, choroidal folds, and hyperopic shifts observed in astronauts after long-duration space flight. Ophthalmology 118(10):2058–2069. https://doi.org/10.1016/j.ophtha.2011.06.021
Minard CG, de Carvalho MF, Iyengar MS (2011) Optimizing medical resources for spaceflight using the integrated medical model. Aviat Space Environ Med 82(9):890–894
Oman CM (1998) Sensory conflict theory and space sickness: our changing perspective. J Vestib Res 8(1):51–56
Putcha L (2009) Data mining – pharmacotherapeutics of space motion sickness
Putcha L, Berens KL, Marshburn TH, Ortega HJ, Billica RD (1999) Pharmaceutical use by U.S. astronauts on space shuttle missions. Aviat Space Environ Med 70(7):705–708
Putcha L, Taylor P, Daniels V, Pool S (2016) Clinical pharmacology and therapeutics. In: Nicogossian AE (ed) Space physiology and medicine: from evidence to practice, 4th edn. Springer, New York p 323
Shende C, Smith W, Brouillette C, Farquharson S (2014) Drug stability analysis by Raman spectroscopy. Pharmaceutics 6(4):651–662. https://doi.org/10.3390/pharmaceutics6040651
Smith SM, Zwart SR (2008) Nutritional biochemistry of spaceflight. Adv Clin Chem 46:87–130
Smith SM, Heer MA, Shackelford LC, Sibonga JD, Ploutz-Snyder L, Zwart SR (2012) Benefits for bone from resistance exercise and nutrition in long-duration spaceflight: evidence from biochemistry and densitometry. J Bone Miner Res 27(9):1896–1906. https://doi.org/10.1002/jbmr.1647
Stingl JC, Welker S, Hartmann G, Damann V, Gerzer R (2015) Where failure is not an option -personalized medicine in astronauts. PLoS One 10(10):e0140764. https://doi.org/10.1371/journal.pone.0140764
Stuster JW (1996) Bold endeavors: behavioral lessons from polar and space exploration. Naval Institute Press, Annapolis
Thornton WE (2011) A rationale for space motion sickness. Aviat Space Environ Med 82(4):467–468
Watkins S, Barr Y, Kerstman E (2011) The space medicine exploration medical conditions list. In: 18th IAA humans in space symposium. IAA, Houston
WHO (2017) World health organization model list of essential medicines. http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed 4 Apr 2018, 20th list
Wilson JW (2000) Overview of radiation environments and human exposures. Health Phys 79(5):470–494
Wotring VE (2010) Evidence Book: Pharmacology Risk Report National Aeronautics and Space Administration, HRP-47060, Lyndon B. Johnson Space Center Houston, Texas
Wotring VE (2012) Space pharmacology. Springer briefs in space development. Springer, New York
Wotring V (2015a) Dose tracker application for monitoring medication usage, symptoms, and adverse effects during missions. NASA Johnson Space Center. https://www.nasa.gov/mission_pages/station/research/experiments/1933.html. Accessed 4 Apr 2018
Wotring VE (2015b) Medication use by U.S. crewmembers on the international Space Station. FASEB J 29(11):4417–4423. https://doi.org/10.1096/fj.14-264838
Wotring VE (2016) Chemical potency and degradation products of medications stored over 550 earth days at the international space station. AAPS J 18(1):210–216. https://doi.org/10.1208/s12248-015-9834-5
Zeitlin C, Hassler DM, Cucinotta FA, Ehresmann B, Wimmer-Schweingruber RF, Brinza DE, Kang S, Weigle G, Bottcher S, Bohm E, Burmeister S, Guo J, Kohler J, Martin C, Posner A, Rafkin S, Reitz G (2013) Measurements of energetic particle radiation in transit to Mars on the Mars science laboratory. Science 340(6136):1080–1084. https://doi.org/10.1126/science.1235989
Zhang LF, Hargens AR (2018) Spaceflight-induced intracranial hypertension and visual impairment: pathophysiology and countermeasures. Physiol Rev 98(1):59–87. https://doi.org/10.1152/physrev.00017.2016
Zoldak JT (2016) Medical consumables tracking. NASA Johnson Space Center https://www.nasa.gov/mission_pages/station/research/experiments/1259.html. Accessed 4 Apr 2018
Zwart SR, Launius RD, Coen GK, Morgan JL, Charles JB, Smith SM (2014) Body mass changes during long-duration spaceflight. Aviat Space Environ Med 85(9):897–904. https://doi.org/10.3357/asem.3979.2014
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this entry
Cite this entry
Wotring, V. (2018). Space Pharmacology: How Space Affects Pharmacology. In: Hock, F., Gralinski, M. (eds) Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Springer, Cham. https://doi.org/10.1007/978-3-319-56637-5_68-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-56637-5_68-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56637-5
Online ISBN: 978-3-319-56637-5
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences